{"organizations": [], "uuid": "bd1f6c131a9dca84346f1996cee6795c1529a2be", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180420.html", "section_title": "Archive News &amp; Video for Friday, 20 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-abeona-therapeutics-receives-orpha/brief-abeona-therapeutics-receives-orphan-drug-designation-in-the-european-union-for-abo-202-gene-therapy-program-in-batten-disease-idUSFWN1RX0RS", "country": "US", "domain_rank": 408, "title": "BRIEF-Abeona Therapeutics Receives Orphan Drug Designation In The European Union For ABO-202 Gene Therapy Program In Batten Disease", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.709, "site_type": "news", "published": "2018-04-20T20:48:00.000+03:00", "replies_count": 0, "uuid": "bd1f6c131a9dca84346f1996cee6795c1529a2be"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-abeona-therapeutics-receives-orpha/brief-abeona-therapeutics-receives-orphan-drug-designation-in-the-european-union-for-abo-202-gene-therapy-program-in-batten-disease-idUSFWN1RX0RS", "ord_in_thread": 0, "title": "BRIEF-Abeona Therapeutics Receives Orphan Drug Designation In The European Union For ABO-202 Gene Therapy Program In Batten Disease", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "abeona therapeutics inc", "sentiment": "negative"}, {"name": "european union", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 20 (Reuters) - Abeona Therapeutics Inc:\n* ABEONA THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ABO-202 GENE THERAPY PROGRAM IN BATTEN DISEASE Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-20T20:48:00.000+03:00", "crawled": "2018-04-21T17:57:49.002+03:00", "highlightTitle": ""}